Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Immuron Limited ( (AU:IMC) ) has issued an announcement.
Immuron Limited reported significant sales growth for its product Travelan® during the December 2024 quarter. The product, which aims to reduce the risk of travelers’ diarrhea, saw a 70% increase in global sales compared to the previous quarter, with notable increases in both the Australian and North American markets. This growth is attributed to expanded distribution channels, including nine new pharmacy banner groups in Australia and ten pharmacy/grocery retailers in Canada, as well as increased sales through Amazon in the US. This strong performance underscores Immuron’s strengthened market positioning and potential for continued expansion.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The company is globally integrated and offers products like Travelan®, an over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract.
YTD Price Performance: 12.50%
Average Trading Volume: 31,579
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €13.74M
For an in-depth examination of IMC stock, go to TipRanks’ Stock Analysis page.
